Overall characteristics of the cohort
| Variable | No (%) |
| Age at diagnosis | |
| <18 years | 19 (47.5) |
| Median 9.6 | |
| Range 1.2–17.6 | |
| ≥18 years | 21 (52.5) |
| Median 37 | |
| Range 18.9–89.2 | |
| Gender | |
| Male | 25 (62.5) |
| Female | 15 (37.5) |
| Tumour site | |
| Cerebral hemispheres | 27 (67.5) |
| Diencephalon | 3 (7.5) |
| Cerebellum | 7 (17.5) |
| Brain stem | 3 (7.5) |
| Integrated diagnosis WHO 2021 | |
| Circumscribed astrocytic glioma | |
| PA | 9 (22.5) |
| PXA | 4 (10) |
| Paediatric-type diffuse LGG | |
| PLNTY | 3 (7.5) |
| DLGG, MAPK | 4 (10) |
| Angiocentric glioma | 1 (2.5) |
| Paediatric-type diffuse HGG | |
| Infant-type hemispheric glioma* | 2 (5) |
| Adult-type diffuse glioma | |
| GBM | 9 (22.5) |
| ODG | 1 (2.5) |
| Astrocytoma | 1 (2.5) |
| Glioneuronal tumour | |
| GG | 2 (5) |
| Not elsewhere classified | 4 (10) |
| Histological grade | |
| Low (1 and 2) | 24 (60) |
| High (3 and 4) | 16 (40) |
| Total | 40 |
*Included one low grade and one high grade.
DLGG, MAPK, diffuse low-grade glioma MAPK pathway-altered; GBM, glioblastoma; GG, ganglioglioma; HGG, high-grade glioma; LGG, low-grade glioma; ODG, oligodendroglioma IDH-mutant 1p/19q-codeleted; PA, pilocytic astrocytoma; PLNTY, polymorphous low-grade neuroepithelial tumour of the young; PXA, pleomorphic xanthoastrocytoma.